Related Experiment Video

Updated: May 31, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Lipoprotein (a) and other Lipid Profile in Patients with Thrombotic Stroke: Is it a Reliable Marker?

Shashidhar K Nagaraj1, Pareenta Pai, Gopalakrishna Bhat

  • 1Department of Biochemistry, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka, India.

Journal of Laboratory Physicians
|June 25, 2011
PubMed

Insights

This study found no significant differences in lipoprotein (a) or lipid profiles between thrombotic stroke patients and controls. Further research is needed to clarify lipoprotein (a)

Area of Science:

  • Cardiovascular Research
  • Neurology
  • Clinical Biochemistry

Background:

  • Cerebrovascular disease (CVD) and coronary heart disease (CHD) are leading causes of mortality.
  • Elevated Lipoprotein (a) [Lp(a)] is a known risk factor for CHD, but its role in CVD is not well-defined.

Purpose of the Study:

  • To investigate the association between Lipoprotein (a) [Lp(a)] and lipid profiles in patients with thrombotic stroke.
  • To compare these markers between acute-phase thrombotic stroke patients and control groups.

Main Methods:

  • A case-control study involving 21 thrombotic stroke patients and 18 age/sex-matched controls.
  • Serum analysis included total cholesterol, triglycerides, HDL-C, LDL-C, Lp(a), and fasting blood glucose.
  • Statistical analysis employed Student's t-test with significance set at P < 0.05.

Main Results:

  • No statistically significant differences were observed in serum lipid profiles or Lp(a) levels between thrombotic stroke patients and controls.
  • The most frequent stroke incidence was observed in the 70-80 year age group.

Conclusions:

  • The study did not establish a significant association between Lp(a) or lipid profiles and thrombotic stroke in the studied population.
  • Associated risk factors like diabetes, hypertension, and family history were noted.
  • Further research is recommended to determine the significance of serum Lp(a) as a risk factor for thrombotic stroke.
Abstract

Keywords:
Lp(a)lipid profilethrombotic stroke

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...